News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
First and only PARP inhibitor to improve overall survival in early breast cancer
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aims to become India’s leading cancer testing company
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Iskra has held leadership positions across Central & Eastern Europe, Eurasia, Middle East & Africa at AstraZeneca
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
Subscribe To Our Newsletter & Stay Updated
